Brent has his tissue tested through FoundationOne. The results are back and he was given them today at MD Anderson. It is a possible reason he has stayed somewhat stable while on MEK by GSK. The report states his tumors bearng NF1 Mutations may therefore be sensitive to mTOR ad MAPK inhibitor. The report goes on to say besides gene alteration NF1 loss, there is
I know this doesnt mean much to many but it is identifing his genomic profile and it reported that there is no BRAF KIT or NRAS detected.
There are trials targeting mTOR and CDKN2A that we can look into.
Viewing 1 post (of 1 total)
The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.